Hetero launches 'Favipiravir' in India for mild to moderate Covid-19 treatment

Hyderabad-based Hetero Labs, one of India’s leading generic pharmaceutical companies and the world’s largest producer of antiretroviral drugs, announced the launch of generic anti-viral drug favipiravir in India for Covid treatment.

Hetero has launched it under the brand name ‘Favivir’. It will be used for the treatment of mild to moderate coronavirus patients.

The drugmaker has already secured manufacturing and marketing approval for favipiravir from the Drug Controller General of India (DCGI).

Favivir is the



second drug developed by Hetero after Covifor (Remdesivir), which is also used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes.

Favivir further improves treatment accessibility to a significant amount of Covid-19 patients who have mild to moderate symptoms.

Hetero’s Favivir will be priced at Rs. 59 per tablet and is likely to be available at most drug stores, hospital pharmacies and retail medical outlets across the country. However, a mandatory prescription is needed to obtain the drug.